NIFTY 50▲22,147.00
151.15 (0.69%)
SENSEX▲73,088.33
599.34 (0.83%)
NIFTY BANK▲47,574.15
504.70 (1.07%)
TATA MOTORS▼963.20
-8.15 (-0.84%)
INDIAN RAILWAY FINANCE CORP▼141.00
-0.95 (-0.67%)
SUZLON ENERGY▼39.35
-1.80 (-4.37%)
TATA POWER▼428.10
-1.65 (-0.38%)
TATA STEEL▲162.10
2.05 (1.28%)
YES BANK▲23.95
0.05 (0.21%)
INDIAN RENEWABLE ENERGY▼160.70
-2.45 (-1.50%)
RELIANCE INDUSTRIES▲2,940.25
11.60 (0.40%)
RELIANCE POWER▼28.05
-0.65 (-2.26%)
HDFC BANK▲1,531.30
36.60 (2.45%)
RAIL VIKAS NIGAM▼258.45
-1.45 (-0.56%)
VODAFONE IDEA▼12.90
-0.30 (-2.27%)
JIO FIN SERVICES LTD▼370.10
-8.30 (-2.19%)
ADANI POWER▼594.55
-3.55 (-0.59%)
ZOMATO▲189.20
4.00 (2.16%)
NHPC▼87.15
-2.35 (-2.63%)
INDIAN RAILWAY TOURISM CORP▼992.00
-0.95 (-0.10%)
STATE BANK OF INDIA▲750.45
5.65 (0.76%)
INDIAN OIL CORP▼166.65
-2.35 (-1.39%)
MRF▼1,29,157.65
-73.85 (-0.06%)
ITC▲424.75
5.90 (1.41%)
ADANI GREEN ENERGY▼1,770.05
-5.40 (-0.30%)
ADANI ENTERPRISES▲3,026.95
7.65 (0.25%)
JAIPRAKASH POWER VENTURES▼17.05
-0.15 (-0.87%)
ADANI PORT & SEZ▲1,310.00
14.45 (1.12%)
Ajanta Pharma Share Price
AJANTPHARM
₹2,085.40+₹6.55 (0.32%) Past YearLast updated on 19 Apr, 2024 | 03:46 PM IST
₹2,069.15₹2,107.95
LH
What’s in news?
Company overview
About
Market cap
| Open₹2,078.85 | Close₹2,078.85 |
Circuit range₹2,494.60 - ₹1,663.10 | Day range₹2,069.15 - ₹2,107.95 | Year range₹1,246.75 - ₹2,353.95 |
Volume34,465 | Avg. traded₹2,084.27 | Revenue (12m)₹4,036 Cr |
Ajanta PharmaAjanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
Read more
Ajanta Pharma Key indicators
52 week high₹2,353.95 | 52 week low₹1,246.75 | P/E ratio35.69 |
P/B ratio7.09 | ROE17.42% | ROCE21.98% |
Dividend yield0.34% | Debt/Equity ratio | EPS44.38 |
Learn more
Featured in
Investment checklist: (4/6)
Equity returns
Dividend returns
Safety factor
Growth factor
Debt vs Equity
Profit factor
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily
Analyst ratings:
Analyst ratings:
83%
Hold
9%
Sell
8%
This analysis is based on the reviews of 12 experts in the last 7 days
Fundamentals
Financial ratios
Operating profit margin23.99% | Net profit margin16.11% |
ROE17.42% | ROA13.3% |
ROCE21.98% |
Learn more
Revenue statement
All values are in ₹ Crores (Cr)No data available at the moment
Cash flow
All values are in ₹ Crores (Cr)No data available at the moment
Balance sheet
All values are in ₹ Crores (Cr)No data available at the moment
Ajanta Pharma Share Price history
Day | Open | Close | Day’s change |
---|---|---|---|
Thu, Apr 18 2024 | ₹2,064.40 | ₹2,078.85 | |
Tue, Apr 16 2024 | ₹2,098.50 | ₹2,064.95 | -1.62% |
Mon, Apr 15 2024 | ₹2,112.10 | ₹2,117.75 | |
Fri, Apr 12 2024 | ₹2,151.60 | ₹2,115.30 | -1.72% |
Wed, Apr 10 2024 | ₹2,150.65 | ₹2,139.65 | -0.51% |
Tue, Apr 9 2024 | ₹2,146.70 | ₹2,150.55 | |
Mon, Apr 8 2024 | ₹2,187.80 | ₹2,135.50 | -2.45% |
Fri, Apr 5 2024 | ₹2,172.00 | ₹2,181.60 |
Events
Corporate actions
Dividend • ₹26/share
Ex date 08 Feb 2024
Dividend • ₹10/share
Ex date 04 Aug 2023
Dividend • ₹15/share
Ex date 04 Aug 2023
Dividend • ₹7/share
Ex date 11 Nov 2022
Bonus • 1:2
Ex date 22 Jun 2022
Dividend • ₹9.5/share
Ex date 09 Nov 2021
Learn more